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Abstract
Background: Innate T helper type 2 (Th2) immune responses mediated by interleukin (IL)-33, thymic stromal
lymphopoietin (TSLP), and IL-25 have been shown to play an important role in pulmonary fibrosis of animal
models; however, their clinical implications remain poorly understood.
Methods: TSLP, IL-25, and IL-33 concentrations were measured in bronchoalveolar lavage fluids obtained from
normal controls (NCs; n = 40) and from patients with idiopathic pulmonary fibrosis (IPF; n = 100), non-specific
interstitial pneumonia (NSIP; n = 22), hypersensitivity pneumonitis (HP; n = 20), and sarcoidosis (n = 19).
Results: The TSLP and IL-33 levels were significantly higher in patients with IPF relative to the NCs (p = 0.01
and p = 0.0001, respectively), NSIP (p = 4.95E − 7 and p = 0.0002, respectively), HP (p = 0.00003 and p = 0.000005,
respectively), and sarcoidosis groups (p = 0.003 and p = 0.0001, respectively). However, the IL-25 levels were not
significantly different between NC and IPF group (p = 0.432). Receiver operating characteristic curves of the TSLP
and IL-33 levels revealed clear differences between the IPF and NC groups (AUC = 0.655 and 0.706, respectively), as
well as between the IPF and the other lung disease groups (AUC = 0.786 and 0.781, respectively). Cut-off values of
3.52 pg/μg TSLP and 3.77 pg/μg IL-33 were shown to differentiate between the IPF and NC groups with 99.2 and
94.3% accuracy. Cut-off values of 4.66 pg/μg TSLP and 2.52 pg/μg IL-33 possessed 99.4 and 93.2% accuracy for
differentiating among the IPF and other interstitial lung disease groups.
Conclusions: Innate immune responses may be associated with the development of IPF. Furthermore, the IL-33
and TSLP levels in BAL fluids may be useful for differentiating IPF from other chronic interstitial lung diseases.
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Background
Idiopathic interstitial pneumonia is an umbrella term
used to classify a group of lung diseases of unknown eti-
ology characterized by the accumulation of inflammatory
cells and fibrosis in the pulmonary parenchyma and in-
terstitium. Among them, idiopathic pulmonary fibrosis
(IPF) is characterized by irreversible fibrosis, resulting in
gradual deterioration and poor prognosis, for which few
effective therapeutics exist [1]. A variety of factors in
combination with a permissive genetic background such
as MUC5B are thought to play a role in the development
of pulmonary fibrosis [2]. The initial injury process and
secondary fibrosis development likely begins as the
result of alveolar epithelial injury due to exposure to en-
vironmental triggers, including cigarette smoke [3], par-
ticles [4], occupational dust [5], or chemical fumes [5],
radiotherapy [6], chemotherapy [6]. Endogenous triggers,
include obstructive sleep apnea, chronic graft-versus-
host disease and connective tissue disease followed by
abnormal repair. These triggers are capable of inducing
both innate and adaptive immune responses [7].
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The epithelium of the respiratory tract forms a large
surface area that maintains intimate contact with the
environment, serving as a primary participant in innate
immunity [8, 9]. IL-33, IL-25 and Thymic stromal
lymphopoietin (TSLP) are the main cytokines involved
in the innate immune response by the epithelium [8].
Recent studies have demonstrated a clear role for these
cytokines in both the induction and amplification of
Th2-mediated immunity [10–12] and lineage-negative
type 2 innate lymphoid cells (ILC2s), which also produce
IL-13: the dominant inducer of fibrosis in several
chronic lung diseases [13].
In animal models, the lungs of bleomycin-treated mice
exhibit a substantial accumulation of IL-33-positive cells
[14] along with over-production of mature IL-33 by the
ILC of the lungs [15]. IL-33 protein and mRNA levels
are significantly higher in the BAL fluids of patients with
IPF relative to healthy controls [14, 16]. In addition to
IL-33, TSLP has emerged as a candidate cytokine in the
pathogenesis of pulmonary fibrosis by the elevated TSLP
levels seen in both systemic sclerosis [17, 18]. TSLP and
its receptor are highly upregulated in IPF lung [19]. Like
IL-33 and TSLP, expression of IL-25 is also increased in
human IPF lung tissue and IL-25 levels were significantly
increased in the BAL fluids of patients with IPF [20].
Despite the relations of the pulmonary fibrosis with
IL-25, IL-33, and TSLP, the clinical implications of these
cytokine remain poorly defined due to the small number
of subjects (less than 15) examined in the previous stud-
ies [14, 16, 18–20]. Here, we measured the IL-25, IL-33,
and TSLP levels in a relatively large cohort of patients
with IPF and other interstitial lung diseases, including
non-specific interstitial pneumonia (NSIP), hypersensi-
tivity pneumonitis (HP), and sarcoidosis in order to




The BAL fluids were obtained from the biobank of Soon-
chunhyang University Hospital, Bucheon, Korea. All rele-
vant study protocols were approved by the Ethics
Committee of Soonchunhyang University Hospital (ap-
proval no. SCHBC-IRB-2015-08-25 and schbc-biobank-
2015-013-01, schbc-biobank-2015-013-02). Informed writ-
ten consent was obtained from each patient prior to
inclusion in this study. The diagnostic criteria for IPF, NSIP,
HP, and sarcoidosis were based on the international con-
sensus statement [1, 21–23], and our previous publication
[24]. All subjects were examined by physicians to obtain
their medical history, followed by a chest x-ray, pulmonary
function tests, high-resolution chest computed tomography
(HRCT), and blood tests to exclude collagen vascular dis-
eases. None of the patients with IPF exhibited any evidence
of underlying collagen vascular diseases based on either
clinical manifestations or laboratory tests. IPF was diag-
nosed by the presence of usual interstitial pneumonia (UIP)
patterns in the pathological specimen (surgical IPF) and/or
by the presence of typical clinical and HRCT features in
patients not subjected to surgical lung biopsy (clinical/
radiological IPF). Two pathologists examined each slide in-
dependently after being informed of the patient’s age, sex,
and HCRT results.
The pathologic recognition of the NSIP pattern in-
cluded two major aspects: (1) recognition of characteris-
tic histological features; and (2) exclusion of other
patterns of interstitial lung diseases (ILD) as described
in the ATS/ERS 2002 classification [21], and the modi-
fied version on the histologic definition of NSIP [25]. HP
was diagnosed by the presence of compatible clinical man-
ifestations with a non-necrotizing granulomatous intersti-
tial bronchiolocentric pneumonitis [22]. The diagnosis of
sarcoidosis was made on the basis of compatible clinical
pictures in combination with the histologic demonstration
of non-caseating granulomas [23]. Definitive diagnosis of
HP or sarcoidosis required the exclusion of other diseases
capable of producing a similar histological picture, with
biopsies stained using acid fast bacilli and Gömöri
methenamine silver to rule out microorganisms and fungi,
respectively.
All study subjects were evaluated using serial forced
vital capacity (FVC) and diffusing capacity of the lungs
for carbon monoxide (DLCO) measurements. The an-
nual rate of FVC decline (dFVC%/year) was calculated
as follows: (last FVC − baseline FVC)/baseline FVC/year.
Healthy controls were comprised of patients’ spouses
and hospital personnel with no evidence of respiratory
symptoms, as determined by a screening questionnaire,
a predicted FEV1 and FVC > 80%, and normal chest
radiogram results.
Bronchoalveolar lavage fluids procedure
BAL was obtained from the most significantly involved
segments as determined by HRCT in the absence of im-
munosuppressive therapies or in the right middle lobe
from NCs, as described previously [24, 26]. Total cell
count was measured using a hematocytometer chamber
[27]. Slides of the BAL cells prepared by cytocentri-
fuge were air-dried, fixed in methanol, and stained
with Diff-Quik®, and a differential count of 500 cells
was performed. Cell pellets were separated from the
supernatants using centrifugation at 500 × g for 5 min,
and the supernatants were stored −80 °C.
Enzyme-linked immunosorbent assays (ELISAs) for TSLP,
IL-25, and IL-33
Cytokine concentrations were measured using quantita-
tive sandwich enzyme immunoassays for IL-25 (Bosterbio,
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Pleasanton, CA, USA), IL-33, and TSLP (R&D Systems,
Minneapolis, MN) according to the manufacturer’s rec-
ommendations. Low detection limits were defined as
10 pg/mL IL-25, 0.52 pg/mL IL-33, and 3.46 pg/mL TSLP;
values below these thresholds were recorded as 0 pg/mL.
Coefficients of variance of inter- and intra-assays
were <15%. Protein concentrations of BAL fluids
were measured using a Micro BCA Protein Assay
Kit (Pierce, Rockford, IL, USA).
Statistical analysis
Data were analyzed using SPSS v. 20.0. The normality of
the distribution was tested using the Shapiro–Wilk test.
Comparisons were performed using the Kruskal–Wallis
test and a post-hoc analysis; a Mann–Whitney U test
was conducted as the nonparametric test. A receiver
operating characteristic (ROC) curve, area under the
curve (AUC), and a cut-off value were calculated using
MedCalc [28]. Correlations between the IL-25, IL-33,
and TSLP levels with the clinical outcomes were ana-
lyzed using Spearman’s correlation coefficient analysis.
Values of p < 0.05 were considered to indicate statistical
significance.
Results
Comparison of the clinical characteristics between the
study subjects
BAL samples were obtained from subjects with IPF
(n = 100), NSIP (n = 22), hypersensitivity pneumonitis
(n = 20), and sarcoidosis (n = 19), along with NCs (n = 40)
(Table 1). The IPF group consisted of 54 surgical and 46
clinical/radiological IPF patients, with no significant differ-
ences in clinical or physiological parameters between the
two groups (Additional file 1: Table S1). Patients with IPF,
NSIP, HP, and sarcoidosis exhibited significantly higher
total cell counts, higher numbers of macrophages, neutro-
phils, and eosinophils in the BAL fluids, and lower FVC
values relative to the controls (p < 0.05) (Table 1). The pa-
tients with NSIP, HP, and sarcoidosis exhibited signifi-
cantly higher numbers of lymphocytes in their BAL fluids
compared to those in IPF (p < 0.05, Table 1). Neutrophil
count was significantly higher in NSIP and HP when com-
pared with sarcoidosis (p < 0.05).
Comparison of TSLP, IL-33, and IL-25 protein levels
among the groups
IL-33 was detected in 36 of 40 NCs, 96 of 100 patients
with IPF, 20 of 22 patients with NSIP, 14 of 20 patients
with HP, and 15 of 19 patients with sarcoidosis (Fig. 1).
TSLP was detected in 23 of 40 NCs, 100 of 100 patients
with IPF, 18 of 22 patients with NSIP, 18 of 20 patients
with HP, and 18 of 19 patients with sarcoidosis. The
median levels (interquartile ranges) of TSLP and IL-33
normalized to the total protein concentration were sig-
nificantly higher in the IPF group relative to the NCs
[9.27 (3.77–27.58 pg/μg) vs. 4.49 (0.31–16.04 pg/μg); p =
0.01, and 4.13 (0.92–12.03 pg/μg) vs. 1.15 (0.63–2.66 pg/
μg); p = 0.0001, respectively], NSIP [1.34 (0.39–4.51 pg/
Table 1 Clinical characteristics of the study participants who underwent bronchoalveolar lavage
Items Normal controls IPF NSIP HP Sarcoidosis
No. 40 100 22 20 19
Age (year) 55 (35–72) 63.8 (32–86)* 60.1 (39–70) 51.3 (28–70) 43.3 (28–69)
Sex (male/female) 14/26 63/37 9/13 10/10 10/9
Smoking (CS/ES/NS) 9/12/19 22/29/44 2/5/12 3/3/12 5/2/9
Follow-up duration (years) ND 4.1 (2.1–6.3) ND ND ND
FVC (% pred.) 106.1 (87.0–119) 75.0 (63.7–83.0)* 78.0 (66.0–91.8)* 64.5 (57.0–82.5)* 77.0 (65.0–86.0)*
FEV1 (% pred.) 102.1 (88.2–117) 89.0 (77.5–100.5)* 85.0 (73.8–101.3)* 74.5 (64.3–92.0)* 85.0 (64.0–101.0)*
DLCO (% pred.) NA 64.0 (38.5–72.5)* 76.0 (59.0–92.0)* 67.0 (55.0–90.0)* 75.5 (57.8–84.5)*
dFVC (%/year) NA −7.0 (−16.5–0.0) NA NA NA
BAL total cell count (104/mL) 3.46 ± 0.82 8.83 ± 2.09* 17.64 ± 3.86* 13.03 ± 3.78* 8.45 ± 3.78*
Macrophages (104/mL) 3.02 ± 0.41 7.37 ± 1.61* 11.51 ± 3.07* 8.25 ± 2.38* 6.76 ± 3.79*
Neutrophils (104/mL) 0.21 ± 0.047 1.35 ± 0.40* 2.31 ± 1.01*,*** 3.14 ± 2.36*,*** 0.45 ± 0.16*,***
Eosinophils (104/mL) 0.02 ± 0.006 0.48 ± 0.16* 0.45 ± 0.14* 0.41 ± 0.19* 0.11 ± 0.07*
Lymphocytes (104/mL) 0.02 ± 0.006 0.17 ± 0.65* 2.68 ± 0.14*,** 2.20 ± 0.19*,** 2.17 ± 0.24*,**
DLCO was measured in 76 of 100 subjects with IPF, 19 of 22 subjects with NSIP, 18 of 20 subjects with HP and 17 of 19 subjects with sarcoidosis
Patient characteristics and pulmonary function test, shown as median (inter-quartile range), among the normal controls, IPF, NSIP, HP, and sarcoidosis groups were
calculated with a Kruskal–Wallis analysis of variance (ANOVA) with the Mann–Whitney U as the post-hoc test. Bronchoalveolar lavage (BAL) cell numbers, shown
as mean ± standard error of the mean (SEM), among the 5 groups were calculated with a one-way ANOVA and the Tukey’s honestly significant difference test as
the post-hoc test
IPF idiopathic pulmonary fibrosis, NSIP non-specific interstitial fibrosis, HP hypersensitivity pneumonitis, CS/ES/NS current-smoker/ex-smoker/never-smoker, ND not
determined, dFVC (%)/year annual decline rate of forced vital capacity (FVC)
Significance: compared with control: *P < 0.05, compared with IPF: **P < 0.05, compared with NSIP and HP: ***P < 0.05
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μg); p = 4.95E − 7, and 0.82 (0.13–1.5 pg/μg); p = 0.0002,
respectively], HP [1.42 (0.75–4.48 pg/μg); p = 0.00003,
and 0.17 (0.31–1.73 pg/μg); p = 0.000005, respectively],
and sarcoidosis groups [3.82 (2.0–6.53 pg/μg), p = 0.003,
and 0.4 (0.06–1.6 pg/μg), p = 0.0001, respectively] (Fig. 1).
The levels of IL-25 normalized to the total protein
concentration were not significantly different between
a subset of 24 NCs and 48 patients with IPF [8.39
(0.54–33.23) pg/μg vs. 0.0 (0.0–8.39) pg/μg, p = 0.432]
(Additional file 2: Figure S1).
The ROC curves for TSLP and IL-33 demonstrated a
clear difference between the IPF and NC groups (TSLP:
AUC = 0.655; IL33: AUC = 0.706) (Fig. 2a and b), as well
as among the patients with IPF and those with other
interstitial lung diseases (n = 61, TSLP: AUC = 0.786, and
IL-33: AUC = 0.781) (Fig. 2c and d). Cut-off values of
3.52 pg/μg TSLP and 3.77 pg/μg IL-33 were shown to
differentiate between the IPF and NC groups with 99.2
and 94.3% accuracy (96.7 and 80% specificity, respect-
ively, with 100% sensitivity), while the cut-off values of
4.66 pg/μg TSLP and 2.52 pg/μg IL-33 possessed 99.4
and 93.2% accuracy (98.4 and 90.2% specificity and 100
and 95% sensitivity, respectively) for differentiating the
IPF from the other interstitial lung disease groups. There
were no evident correlations between the TSLP and IL-
33 concentrations in patients with IPF (Fig. 3), nor were
any correlations observed among these two cytokines
and any clinical or physiological outcomes such as dFVC
(%/year) or cell numbers in the BAL fluid (Additional
file 1: Table S2).
When the patients were divided into 4 groups using
median IL-33 (4.13 pg/μg) and TSLP (9.25 pg/μg) levels
as cut-offs, 22 subjects exhibited elevated levels of both
cytokines, while 22 subjects showed levels below the me-
dians for both cytokines. A total of 28 subjects exhibited
elevated levels of IL-33 only, while 28 subjects had
elevated TSLP only (Fig. 3). There were no significant
differences in the clinical and physiological profiles
among the four groups (Table 2).
Comparison of TSLP, IL-33 and IL-25 protein levels among
NSIP, HP, and sarcoidosis
IL-33 was slightly decreased in HP and sarcoidosis com-
pared with NCs (0.17 (0.31–1.73 pg/μg), 0.4 (0.06–
1.6 pg/μg) vs. 1.15 (0.63–2.66 pg/μg); p = 0.006 and p =
0.048, respectively). TSLP was lower in NSIP, and HP
than NCs (1.34 (0.39–4.51 pg/μg), 1.42 (0.75–4.48 pg/
μg) vs. 4.49 (0.31–16.04 pg/μg); p = 0.001, and p = 0.031).
There was no difference of IL-33, TSLP and IL-25 levels














































Fig. 1 Thymic stromal lymphopoietin (TSLP) and interleukin-33 (IL-33) protein concentrations in bronchoalveolar lavage (BAL) fluid. a TSLP protein
was detected in 23 of 40 normal controls (NCs), 100 of 100 patients with idiopathic pulmonary fibrosis (IPF), 18 of 22 patients with non-specific
interstitial pneumonia (NSIP), 18 of 20 patients with hypersensitivity pneumonitis (HP), and 18 of 19 patients with sarcoidosis. The open and
closed circles indicate detectable TSLP protein levels and those below the lower limit of detection (>3.46 pg/mL), respectively. b IL-33 protein
was detected in 36 of 40 NCs, 96 of 100 patients with IPF, 20 of 22 patients with NSIP, 14 of 20 patients with HP, and 15 of 19 patients with
sarcoidosis. The open and closed circles indicate detectable IL-33 protein levels and those below the lower limit of detection (>0.519 pg/mL),
respectively. The data are presented as median values with the 25th and 75th percentiles
Lee et al. BMC Pulmonary Medicine  (2017) 17:39 Page 4 of 9
(p > 0.05) (Fig. 1). There was no correlation of IL-33,
TSLP and IL-25 levels with physiologic parameters and
BAL cell counts in each group.
Discussion
In this study, we demonstrated that IL-33 and TSLP
were significantly elevated in the lungs of patients with
IPF. These observations strongly support the notion of
accentuated innate immune activation in the develop-
ment of IPF, an effect commonly seen in animal models
of acute lung injury and fibrosis. A wide variety of stud-
ies have demonstrated the importance of Th2 cells: IL-4,
IL-5, and IL-13 have been causally linked to the develop-
ment of fibrosis [13]. Recent studies have demonstrated
a clear role of IL-33 and TSLP in both the adaptive and
innate immune response. IL-13 is highly detected in the
bronchoalveolar lavage (BAL) fluid of patients with IPF,
and IPF fibroblasts are hyper-responsive to IL-13.
Furthermore, the combined over-expression of both IL-
13 and IL-13 receptor α1 directly correlates with disease
severity [26]. TGF-β and IL-13 are essential for the de-
velopment of pulmonary fibrosis by promoting differen-
tiation of myofibroblast and stimulating production of
extracellular matrix, such as collagens. Although IL-33,
TSLP, and IL-25 might exert no direct induction of
epithelial-mesenchymal transition, these cytokines are
Fig. 2 Receiver operating characteristic (ROC) curve analysis for the diagnosis of IPF. a The ROC curve of the TSLP protein concentration in the
patients with IPF and the controls (Area under the curve [AUC] = 0.655, cut-off = 3.52 pg/μg; 99.2% accuracy, 96.7% specificity, 100% sensitivity)
and b IL-33 protein concentration in patients with IPF and the controls (AUC = 0.706, cut-off = 3.77 pg/μg; 94.3% accuracy, 80% specificity, 100%
sensitivity). c ROC curve of the TSLP protein concentrations among patients with IPF and those with other interstitial lung diseases (ILD) (AUC =
0.786, cut-off = 4.66 pg/μg; 99.4% accuracy, 98.4% specificity, 100% sensitivity) and d IL-33 protein concentration in patients with IPF and the other
ILD groups (AUC = 0.781, cut-off = 2.52 pg/μg; 93.2% accuracy, 90.2% specificity, 95% sensitivity)
Fig. 3 Correlation between TSLP and IL-33 levels in bronchoalveolar
lavage fluid from the patients with IPF. Correlations were analyzed
using Spearman’s correlation coefficient analysis. When the patients
were divided into four groups using the median IL-33 (4.13 pg/μg)
and TSLP (9.25 pg/μg) levels as cut-offs, 22 subjects had elevated
levels of both cytokines, while 22 subjects had levels below both
medians and 28 subjects had elevated levels of IL-33 only, while
28 subjects had elevated TSLP only. Differences in the clinical
and physiological profiles among the four groups are presented
in Table 2
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obviously involved in the process of fibrosis via regula-
tion of TGF-β and IL-13. IL-33 polarizes M2 macro-
phages to produce IL-13 and TGF-β and expansion of
ILC2s to producing IL-13 [15]. The interaction of these
cytokines has been well documented in allergic inflam-
mation. IL-33 stimulates the rapid expansion of type 2
innate lymphoid cells (ILC2) producing IL-13 [29], inde-
pendently from the canonical CD4+ T helper 2 cells re-
sponses [30]. In addition to ILC2, eosinophils are
additional sources of IL-13. Bone marrow-derived eosin-
ophils secrete IL-13 in response to IL-33 stimulation in
cutaneous fibrosis [31]. While IL-33 mainly affects the
upstream of IL-13, TSLP acts both upstream and down-
stream of IL-13. TSLP induce conventional Th2 cell
priming through the costimulatory action of OX40 lig-
and [32, 33] and an activation of ILC2 [34, 35] . In
addition, TSLP is a downstream target of IL-13/Stat6
pathway [36]. Thus, the elevation of IL-33 and TSLP in
IPF of our study suggest that these cytokines stimulate
the upstream and downstream signals of IL-13 in con-
cert to potentiate the process of fibrosis in the lung.
In animal models, bleomycin-mediated injury exerted
a synergistic effect with IL-33 on collagen accumulation
in the lung [14]. Bleomycin enhanced the production of
the mature form of IL-33 in lung tissue, while deletion
of the IL-33 receptor (IL-1 receptor-like 1; ST2) attenu-
ated the bleomycin-induced lung inflammation and fi-
brosis [15]. Similar effects were seen following intranasal
administration of a lentiviral construct expressing sol-
uble ST2, resulting in markedly lower levels of pro-
inflammatory and pro-fibrotic mediators, such as IL-4,
IL-13, IL-33, and TGF-β1 along with improved survival
rates in bleomycin-treated mice [37]. Although IL-33 is
constitutively expressed in both epithelial and endothe-
lial cells, IL-33 is clearly induced in the other lung tis-
sues of patients with IPF. The infiltrating cells in and
around the inflammatory lesions and the fibrotic foci,
composed primarily of lymphocytes with occasional
macrophages, neutrophils, and eosinophils, express IL-
33 [14, 16]. In addition to the findings from animal
models, elevated IL-33 levels have been observed in the
BAL fluid from 10 patients with IPF compared with
those from 5 healthy controls [16]. The authors also
demonstrated that primary pulmonary fibroblasts de-
rived from the lungs of the patients with IPF and sys-
temic sclerosis, showed enhanced expression of IL-33
mRNA [16], suggesting that the fibroblasts may be an
important source of IL-33.
Ever since TSLP was first implicated as a driver of Th2
responses in the airways [12], aberrant levels of TSLP
have been observed in a range of airway diseases, such
as asthma, COPD, and nasal polyps [38, 39]. Recently,
TSLP has also emerged as an important cytokine in the
pathogenesis of non-allergic diseases, including both cu-
taneous and lung fibrotic conditions of systemic sclerosis
and IPF [17–19]. While a recent comparison of TSLP
demonstrated no difference in BAL fluids between the
IPF and HP groups [40], the number of subjects was too
small (10 in each group) to draw any meaningful conclu-
sions. Beyond this work, few studies have attempted to
Table 2 Clinical characteristics of the patietns with IPF classifed according to the levels of IL-33 and TSLP
Items IL-33↑, TSLP↓ IL-33↓, TSLP↑ IL-33↑,TSLP↑ IL-33↓, TSLP ↓
No. 28 28 22 22
Age (year) 63.5 (32–76) 67.3 (46–86) 62.5 (44–77) 62.0 (41–75)
Sex (male/female) 17/11 19/9 14 /8 13 /9
Smoking (CS/ES/NS) 7/9/12 7/8/13 2 /10 /10 10/2/7
Follow-up duration (years) 3.5 (2.28–5.53) 3.6 (2.1–5.45) 5.1 (1.6–7.2) 5.5 (2.9–7.6)
FVC (% pred.) 74.5 (61.8–84.8) 70.0 (61.5–81.8) 77.0 (65.0–86.0) 83.5 (65.5–93.0)
FEV1 (% pred.) 81.0 (75.0–100.0) 86.0 (77.0–81.8) 89.0 (79.0–102.5) 97.0 (79.5–106.3)
DLCO (% pred.) 66.0 (53.3–70.5) 46.0 (38.5–73.5) 50.0 (42.0–77.8) 68.0 (59.0–83.0)
dFVC (%)/year −12.0 (−16.0–3.5) −13.0 (−18.3– − 2.8) −8.5 (−13.50– -5.75) −10.0 (−23.5– − 0.5)
BAL total cell count (104/mL) 11.27 ± 7.41 6.10 ± 1.99 5.59 ± 2.38 14.62 ± 6.07
Macrophages (104/mL) 10.50 ± 6.52 5.60 ± 1.54 4.13 ± 1.25 11.19 ± 4.16
Neutrophils (104/mL) 1.97 ± 1.14 1.34 ± 0.78 1.72 ± 0.92 0.47 ± 0.21
Eosinophils (104/mL) 0.56 ± 0.47 0.53 ± 0.28 0.66 ± 0.42 0.12 ± 0.05
Lymphocytes (104/mL) 0.43 ± 0.34 0.12 ± 0.05 0.15 ± 0.06 0.08 ± 0.28
Patient characteristics and pulmonary function test, shown as median (inter-quartile range), among the NC, IPF, NSIP, HP, and sarcoidosis groups were calculated with a
Kruskal–Wallis ANOVA with the Mann–Whitney U as the post-hoc test. BAL cellular differentiation, shown as mean ± SEM, among the 4 groups was calculated with a
one-way ANOVA and the Tukey’s honestly significant difference test as the post-hoc test. Significance: compared with IL-33↑:*P < 0.05
CS/ES/NS current-smoker/ex-smoker/never-smoker, ND not determined, dFVC (%) annual decline rate of forced vital capacity (FVC)
IL-33↑: median of IL-33 > 4.13 pg/ug, IL-33↓ ≤ 4.13 pg/ug
TSLP↑: median of TSLP > 9.25 pg/ug, TSLP↓ ≤ 9.25 pg/ug
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address the clinical relevance of IL-33 and TSLP expres-
sion in the context of IPF or other interstitial lung dis-
eases. Our study clearly demonstrate that both IL-33
and TSLP levels were robustly increased in the patients
with IPF compared with patients afflicted with other
interstitial lung diseases, including HP, NSIP, and sar-
coidosis, suggesting that the enhanced innate immune
responses may be more related with the development of
IPF than the other interstitial lung diseases.
Significant differences have been observed among IPF
and other chronic interstitial lung diseases at both the
mRNA and protein expression levels. More than 1000
genes were shown to be differentially expressed among
IPF and other interstitial lung diseases, including HP
and NSIP [41]; a meta-analysis of four representative
datasets on IPF and sarcoidosis revealed 708 differen-
tially expressed genes [42]. Interestingly, the expression
of TSLP and IL-33 was not significantly different among
the disease groups in any of these studies. The most
likely explanation for the discrepancy between these
mRNA expression studies is the small number of lung
tissues used in the gene expression studies compared to
the large number of BAL fluids in ours.
Similarly, no correlation was found between the TSLP
and IL-33 concentrations in patients with IPF. This may
indicate different cell sources for each of these two cyto-
kines. IL-33 is constitutively expressed in both epithelial
and endothelial cells [43], and can be expressed by sev-
eral other cell types within active lesions [14, 15]. TSLP
is highly expressed by lung epithelial cells [44], but is
also expressed by non-epithelial cell types, including
mesenchymal cells and fibrocytes. Additionally, we ob-
served no correlations between the levels of the two cy-
tokines and the clinical and physiological parameters,
such as lung function deterioration or cell numbers in
the BAL fluid. These data indicate that IL-33 and TSLP
may be more likely to be related to the development of
IPF rather than its severity or progression.
In the present study, IL-25 in BAL fluid was not statisti-
cally different between the patients with IPF and the
normal controls. We therefore did not perform any subse-
quent assessments of IL-25 in other interstitial lung dis-
eases. Pulmonary expression of IL-25 has been shown to
be increased in patients with IPF, and is essential in the
generation of experimental pulmonary fibrosis: IL-25
levels were shown to be higher in the BAL fluid of patients
with IPF compared with a small number of controls [20].
The reason for the discrepancy between this study and
ours is not clear. Prostaglandin E2 (PGE2) exhibits potent
anti-fibrotic activity in the IPF lung [45]. PGE2 directly in-
hibits major pathobiologic functions of effector fibroblasts
including chemotaxis, proliferation, collagen synthesis,
and differentiation to myofibroblasts via E prostanoid re-
ceptor 2– mediated increases in intracellular cyclic AMP
[46]. Derangements of PG synthesis are present in fibrotic
diseases in humans and animal models of pulmonary fi-
brosis. Fibroblasts from IPF patients are unable to upregu-
late the COX-2 enzyme and are thereby deficient in PGE2
production [47]. Thus, diminished PGE2 production and/
or signaling characterize lung fibrosis and are likely to be
pathophysiologically significant. It is unknown whether
IL-33, TSLP and IL-25 are related with PGE2 production
although these cytokines stimulate mast cells to produce a
large quantity of PGD2 [48].
One limitation of our study was the small number of pa-
tients with other interstitial lung diseases, including those
with NSIP, HP, and sarcoidosis. Additionally, long-term
follow up will be necessary to fully address the clinical im-
plications of these cytokines, particularly the survival rate
of IPF. Furthermore, validation studies using other co-
horts’ samples are mandatory to improve the diagnostic
values of IL-33 and TSLP. Finally, the lack of transcrip-
tome analysis in conjunction with these cytokines data
limited our ability to assess some of the potential mecha-
nisms underlying the changes in protein expression.
Conclusions
As innate Th2-like responses have been well documented
in animal models of lung fibrosis, we analyzed the clinical
implications of the enhanced Th2 responses in the pa-
tients with IPF. In the present study, we demonstrated
that IL-33 and TSLP, two important cytokines of the in-
nate immune response, were elevated in the BAL fluids of
the patients with IPF relative to those of the normal con-
trols, as well as the patients with other interstitial lung dis-
eases, including HP, NSIP, and sarcoidosis. The data
presented here strongly support a role for innate immune
activation in the development of IPF.
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